Analysts Anticipate Audentes Therapeutics Inc (BOLD) to Announce ($0.76) EPS
Audentes Therapeutics Inc (NASDAQ:BOLD) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $22.33 for the company and are expecting that the company will post ($0.76) EPS for the current quarter, according to Zacks. Zacks has also assigned Audentes Therapeutics an industry rank of 105 out of 265 based on the ratings given to related companies.
A number of brokerages have commented on BOLD. Piper Jaffray Cos. began coverage on shares of Audentes Therapeutics in a research note on Monday, August 15th. They issued an “overweight” rating and a $24.00 target price on the stock. Cowen and Company began coverage on shares of Audentes Therapeutics in a research note on Monday, August 15th. They issued an “outperform” rating on the stock. Wedbush began coverage on shares of Audentes Therapeutics in a research note on Monday, August 15th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/analysts-anticipate-audentes-therapeutics-inc-bold-to-announce-0-76-eps.html
In other Audentes Therapeutics news, Director Orbimed Advisors Llc purchased 33,334 shares of the stock in a transaction dated Monday, July 25th. The stock was purchased at an average price of $15.00 per share, with a total value of $500,010.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider James E. Flynn purchased 400,000 shares of the stock in a transaction dated Monday, July 25th. The stock was acquired at an average cost of $15.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.
Audentes Therapeutics (NASDAQ:BOLD) traded down 10.952% during trading on Wednesday, reaching $17.115. The company’s stock had a trading volume of 141,242 shares. The company’s 50 day moving average price is $16.50 and its 200-day moving average price is $15.80. The stock’s market cap is $371.82 million. Audentes Therapeutics has a 1-year low of $13.06 and a 1-year high of $20.74.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.